Ascendis Pharma (ASND) announced that the FDA has accepted for review its supplemental biologics license application, or sBLA, in adult growth hormone deficiency, or GHD, for TransCon hGH. The FDA set a Prescription Drug User Fee Act goal date of July 27, 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Reviews Share Structure and Capital Strategy
- Ascendis Pharma price target raised to $207 from $200 at Stifel
- Ascendis Pharma price target lowered to $153 from $160 at TD Cowen
- Ascendis Pharma Reports Strong Q3 2024 Results
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance